A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer

The purpose of this study is to determine if the commonly administered chemotherapeutic agents including cisplatin, carboplatin, oxaliplatin, docetaxel and gemcitabine for solid tumors in clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.

Trial Details

NCT ID
NCT02889666
Phase
PHASE1
Sponsor
Shanghai Jiao Tong University School of Medicine
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Cisplatin
  • Carboplatin
  • Docetaxel
  • Gemcitabine/Carboplatin
  • Gemcitabine/Cisplatin
  • Docetaxel/Oxaliplatin
Locations (sample)
  • Changchun, Jilin, China|43.88,125.32278
  • Shanghai, China|31.22222,121.45806
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Age ≤ 75 years with histologically proven NSCLC
  • No severe major organ dysfunction
  • WHO performance status of 0 or 1
  • No prior cancer chemotherapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →